Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Nov;87(5):796-805.
doi: 10.4269/ajtmh.2012.12-0019. Epub 2012 Oct 1.

Use of multiple data sources to estimate the economic cost of dengue illness in Malaysia

Donald S Shepard, Eduardo A Undurraga, Rosemary Susan Lees, Yara Halasa, Lucy Chai See Lum, Chiu Wan Ng
Review

Use of multiple data sources to estimate the economic cost of dengue illness in Malaysia

Donald S Shepard et al. Am J Trop Med Hyg. 2012 Nov.

Erratum in

  • Am J Trop Med Hyg. 2013 Mar;88(3):606

Abstract

Dengue represents a substantial burden in many tropical and sub-tropical regions of the world. We estimated the economic burden of dengue illness in Malaysia. Information about economic burden is needed for setting health policy priorities, but accurate estimation is difficult because of incomplete data. We overcame this limitation by merging multiple data sources to refine our estimates, including an extensive literature review, discussion with experts, review of data from health and surveillance systems, and implementation of a Delphi process. Because Malaysia has a passive surveillance system, the number of dengue cases is under-reported. Using an adjusted estimate of total dengue cases, we estimated an economic burden of dengue illness of US$56 million (Malaysian Ringgit MYR196 million) per year, which is approximately US$2.03 (Malaysian Ringgit 7.14) per capita. The overall economic burden of dengue would be even higher if we included costs associated with dengue prevention and control, dengue surveillance, and long-term sequelae of dengue.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Three participants in the workshop and Delphi process (Jeremy Brett, Laurent Coudeville, and Shree Jacob) were employees of Sanofi-Pasteur, a company currently developing a dengue vaccine.

Figures

Figure 1.
Figure 1.
Reported and projected cases of dengue in Malaysia, 1988–2010. Reported cases were obtained from the Ministry of Health Malaysia and the World Health Organization Regional Office for the Western Pacific. EF = adjusted dengue cases based on workshop estimates.
See this image and copyright information in PMC

References

    1. Guzman A, Isturiz RE. Update on the global spread of dengue. Int J Antimicrob Agents. 2010;36:S40–S42. - PubMed
    1. Ooi EE, Goh KT, Gubler DJ. Denque prevention and 35 years of vector control in Singapore. Emerg Infect Dis. 2006;12:887–893. - PMC - PubMed
    1. Halstead SB. Dengue. Lancet. 2007;370:1644–1652. - PubMed
    1. Gubler DJ, Meltzer M. Advances in Virus Research. Volume 53. San Diego, CA: Academic Press Inc; 1999. Impact of dengue/dengue hemorrhagic fever on the developing world; pp. 35–70. - PubMed
    1. Shepard DS, Suaya JA. Cost-Effectiveness of a dengue vaccine in Southeast Asia and Panama: preliminary estimates. In: Preedy VR, Watson RR, editors. Handbook of Disease Burdens and Quality of Life Measures. New York: Springer; 2009. pp. 1281–1296.

Publication types